Idiopathic pulmonary arterial hypertension (iPAH) is a rare progressive, life-shortening disease, usually diagnosed at an advanced stage. We hypothesize that patients with iPAH exhibit patterns of health-seeking behavior before diagnosis that will allow the development of earlier identification tools. The Sheffield Pulmonary Hypertension IndeX (SPHInX) project aims to develop a predictive algorithm based on routinely collected healthcare resource utilization (HCRU) data. This report focuses on the initial feasibility of the project, examining whether Hospital Episode Statistics (HES) data from the National Health Service in England have sufficient richness to support the development of an early diagnosis algorithm. This is a two-stage study...
Pulmonary hypertension (PH) is a hemodynamic and pathophysiological condition defined as an increase...
Background and aims Pulmonary hypertension due to left heart disease (PH-LHD) is the most frequent f...
Pulmonary arterial hypertension (PAH), defined as group 1 of the World Heart Organisation (WHO) clas...
Idiopathic pulmonary arterial hypertension is a rare and life-shortening condition often diagnosed a...
Pulmonary arterial hypertension (PAH) is rare and, if untreated, has a median survival of 2–3 years....
Idiopathic pulmonary arterial hypertension (IPAH) is a rare but fatal disease diagnosed by right hea...
The term idiopathic pulmonary arterial hypertension (IPAH) is used to categorize patients with pre-c...
Pulmonary hypertension (PH) has progressively moved from an orphan disease to a significant global h...
Idiopathic pulmonary arterial hypertension (IPAH) is a rare but fatal disease diagnosed by right hea...
BACKGROUND: Among patients meeting diagnostic criteria for idiopathic pulmonary arterial hypertensio...
Objective: Idiopathic pulmonary arterial hypertension (IPAH) remains a devastating and incurable, al...
BACKGROUND: >Despite advances in drug development, life expectancy in idiopathic pulmonary arteri...
Background: Idiopathic pulmonary arterial hypertension (IPAH) is a fatal disorder with a prevalence ...
Pulmonary hypertension (PH) is a hemodynamic and pathophysiological condition defined as an increase...
Background and aims Pulmonary hypertension due to left heart disease (PH-LHD) is the most frequent f...
Pulmonary arterial hypertension (PAH), defined as group 1 of the World Heart Organisation (WHO) clas...
Idiopathic pulmonary arterial hypertension is a rare and life-shortening condition often diagnosed a...
Pulmonary arterial hypertension (PAH) is rare and, if untreated, has a median survival of 2–3 years....
Idiopathic pulmonary arterial hypertension (IPAH) is a rare but fatal disease diagnosed by right hea...
The term idiopathic pulmonary arterial hypertension (IPAH) is used to categorize patients with pre-c...
Pulmonary hypertension (PH) has progressively moved from an orphan disease to a significant global h...
Idiopathic pulmonary arterial hypertension (IPAH) is a rare but fatal disease diagnosed by right hea...
BACKGROUND: Among patients meeting diagnostic criteria for idiopathic pulmonary arterial hypertensio...
Objective: Idiopathic pulmonary arterial hypertension (IPAH) remains a devastating and incurable, al...
BACKGROUND: >Despite advances in drug development, life expectancy in idiopathic pulmonary arteri...
Background: Idiopathic pulmonary arterial hypertension (IPAH) is a fatal disorder with a prevalence ...
Pulmonary hypertension (PH) is a hemodynamic and pathophysiological condition defined as an increase...
Background and aims Pulmonary hypertension due to left heart disease (PH-LHD) is the most frequent f...
Pulmonary arterial hypertension (PAH), defined as group 1 of the World Heart Organisation (WHO) clas...